As the momentum and interest in brain-computer interface (BCI) technologies continue to accelerate, Merge Labs has emerged with an investment from OpenAI in its seed round. Merge Labs says it plans to develop next-generation BCIs capable of interacting with the brain at high bandwidth, integrating with advanced AI, and doing so in ways that are safe and accessible to everyone. Read More
Rhythm Biosciences Ltd. launched a new genetype colorectal cancer risk assessment clinical test that incorporates clinical and lifestyle risk factors alongside its established 140-SNP polygenic risk score to identify people at elevated risk of colorectal cancer. The test supports more targeted screening and complements Melbourne-based Rhythm’s Colostat blood-based CRC detection test, which debuted in Australia in December 2025. Read More
The Centers for Medicare & Medicaid Services has cracked open its coverage policy for transcatheter aortic valve replacement devices a second time, and a wide range of stakeholders are providing feedback. Where the agency will land on questions such as the need for continued evidence development is difficult to predict, however, given that the agency is hearing anything but unanimity on the question. Read More
Once it was considered to be more or less a passive energy-storing device that could double as a cushion. But increasingly, fat is conceptualized as an endocrine organ as much as a tissue type. Now, separate research groups have reported new insights into the functional roles of different fats based on their anatomical location and functional characteristics. Read More
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Endoquest, Diamicron, Henry Schein, Optimed, Orasure, Zylox-Tonbridge. Read More
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: BD, Elekta, Proprio. Read More
Effective Jan. 5, 2026, BioWorld is switching email fulfillment services. While we have made every effort to ensure that all current user subscription details — as well as information on users who have unsubscribed — have been migrated accurately to the new system, there may be a few instances where certain information may not have carried over as expected. If you have any concerns that you received a newsletter in error or if a colleague has not received an expected newsletter, do not hesitate to reach out to our customer care team. Call us:
Americas: 855-258-3279
Europe, Middle East, and Africa: +44 8081 963232
Going forward, if you would like to be unsubscribed, click on the ‘Unsubscribe’ link at the bottom of the emailed newsletter.
